Rheos Medicines
Created in 2018
To investigate (B)
Some signals may appear as inconsistent with a regular activitySocial networks
287 4,740Activities
Technologies
Entity types
Location
245 First St, Cambridge, MA 02142, USA
Cambridge
United States of America
Employees
Scale: 11-50
Estimated: 23
Engaged catalyst
1
0 0Added in Motherbase
5 years, 11 months ago
Value proposition
[Automatic translation follows] Rheos Medicines is a biopharmaceutical company harnessing insights in immunometabolism to develop a novel class of medicines with potential to transform the lives of patients with immune mediated diseases. We are rapidly applying a first-in-field approach in immunometabolism with a comprehensive, systems-biology understanding of the metabolic pathways that drive immune cell function and fate coupled to a biomarker discovery effort with potential to bring precision to the treatment of immune-mediated diseases. Launched in 2018 by Third Rock Ventures with a $60 million Series A financing, Rheos is built on groundbreaking science from pioneers in the field, our passionate team of more than 35 employees is advancing a novel pipeline of immunometabolism drugs, and in December 2019, we entered into a worldwide collaboration with Roche to identify and develop new therapeutics for autoimmune and inflammatory disease. We have brought together leading scientists whose discoveries opened the field of immunometabolism, clinicians with a deep understanding of immune-mediated diseases, and an experienced leadership team that integrates immunology, metabolism, computational biology, and drug discovery to unlock a new frontier in precision medicine for immune mediated disease.
Original language
Rheos Medicines is a biopharmaceutical company harnessing insights in immunometabolism to develop a novel class of medicines with potential to transform the lives of patients with immune mediated diseases. We are rapidly applying a first-in-field approach in immunometabolism with a comprehensive, systems-biology understanding of the metabolic pathways that drive immune cell function and fate coupled to a biomarker discovery effort with potential to bring precision to the treatment of immune-mediated diseases. Launched in 2018 by Third Rock Ventures with a $60 million Series A financing, Rheos is built on groundbreaking science from pioneers in the field, our passionate team of more than 35 employees is advancing a novel pipeline of immunometabolism drugs, and in December 2019, we entered into a worldwide collaboration with Roche to identify and develop new therapeutics for autoimmune and inflammatory disease. We have brought together leading scientists whose discoveries opened the field of immunometabolism, clinicians with a deep understanding of immune-mediated diseases, and an experienced leadership team that integrates immunology, metabolism, computational biology, and drug discovery to unlock a new frontier in precision medicine for immune mediated disease.
SIAP46 : Platform Game Pencetus Claim Promo Bonus Petir Listrik Juga Bom Ada Disini
Siap46 adalah situs pencetus claim promo bonus petir listrik bom yang ada pertama kali hanya di situs disini sudah paten.
https://www.virtualapple.com/
